Filter
186
Text search:
dolutegravir
Featured
Recommendations
20
New Publications
40
Language
Document type
No document type
77
Guidelines
46
Studies & Reports
37
Manuals
7
Strategic & Response Plan
7
Fact sheets
5
Training Material
3
Situation Updates
2
Infographics
2
Countries / Regions
South Africa
9
Global
8
Argentina
7
Malawi
5
Namibia
4
Latin America and the Carribbean
4
Kenya
3
Africa
3
Uganda
2
Brazil
2
Botswana
2
Myanmar / Burma
2
South–East Asia Region
2
Guinea
1
Nigeria
1
Congo, Democratic Republic of
1
Ethiopia
1
Zimbabwe
1
Philippines
1
Somalia
1
Nepal
1
Zambia
1
Thailand
1
Rwanda
1
Mozambique
1
Central African Republic
1
Peru
1
Ukraine
1
Colombia
1
Bolivia
1
Lesotho
1
Chile
1
Western Pacific Region
1
Western and Central Europe
1
Venezuela
1
North America
1
Authors & Publishers
Publication Years
Category
Countries
44
Clinical Guidelines
25
Women & Child Health
4
Public Health
2
Pharmacy & Technologies
2
Key Resources
1
Toolboxes
HIV
123
TB
11
Pharmacy
8
AMR
4
COVID-19
3
NTDs
3
Conflict
2
Refugee
2
Mental Health
2
Malaria
1
Open Forum Infect Dis . 2022 Apr 5;9(5):ofac148.doi: 10.1093/ofid/ofac148. eCollection 2022 May. Dolutegravir HIV drug resistance (HIVDR) data from Africa remain sparse. We reviewed HIVDR results of Malawians on
...
A medida que el tratamiento antirretrovírico con dolutegravir se extiende a más personas que viven con el VIH en el
mundo, adquiere más importancia estimar la frecuencia con que surge la farmacorresistencia adquirida a este
antirretrovírico en
...
WHO’s sentinel surveys of acquired HIV resistance to dolutegravir among people receiving dolutegravir-containing antiretroviral therapy is intended for easy and frequent implementation. Results fr
...
This technical report summarizes the discussions on the status of programmatic transition to tenofovir, lamivudine and dolutegravir (TLD) in low– and middle- income countries, addressing the best practices and major challenges faced by HIV program
...
Avec l’essor des traitements antirétroviraux (TAR) à base de dolutégravir (DTG) pour soigner les personnes vivant avec
le VIH dans le monde, il est important d’estimer la vitesse à laquelle la résistance acquise au DTG apparaît dans les
...
CDC leads an international surveillance effort to estimate the occurrence of HIV drug resistance among people with HIV who are taking dolutegravir (DTG)-based treatments. This surveillance effort utilizes Cyclical Acquired HIV Drug Resistance Survei
...
Em meados de 2021, os programas nacionais de SIDA começaram a fazer a transição do tratamento para crianças que vivem com VIH dolutegravir (DTG) 10 mg sulcado, comprimidos dispersíveis, também conhecido como DTG pediátrico (pDTG). A rápida i
...
WHO’s antiretroviral treatment (ART) clinic-based acquired drug resistance survey method yields robust estimates of HIV viral suppression and acquired HIV drug resistance in adults, children and adolescents taking both dolutegravir and non-
...
July 2021. This publication brings together important clinical and programmatic updates produced by WHO since 2016 and provides comprehensive, evidence-informed recommendations and good practice statements within a public health, rights-based and person-centred approach.
These guidelines bring in
...
Version: 14 March 2019; A one-page reference guide to all the anti-HIV drugs licensed for use in the European Union, with information on formulation, dosing, key side-effects and food restrictions.
The previous edition of the drugs chart is also available to download in Russian.
Developed by the HHS Panel on Treatment of Pregnant Women with HIV Infection and Prevention of Perinatal Transmission—
A Working Group of the Office of AIDS Research Advisory Council (OARAC)
Accessed: 12.02.2020
Medicines and medical devices for 10 000 people for approximately three months
الأدوية الأساسية
recommended
. MSF Essential Drugs Guidelines دليل عملي موجه للأطباء والصيادلة والممرضين والمساعدين الطبيين
